Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 800 of 1048 entries
View as:

Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01474187 Org: User:
Start: 11/30/11 End: 12/31/12 Due: 12/31/13

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Phase: N/A Priority: Normal
NCT ID: NCT04215003 Org: User:
Start: 01/20/20 End: 12/31/24 Due: 12/31/25

A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers

Phase: N/A Priority: Normal
NCT ID: NCT01860508 Org: User:
Start: 02/28/13 End: - Due: -

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05212857 Org: User:
Start: 04/30/22 End: 09/30/24 Due: 09/30/25

Efficacy of Nasogastric Tube Application in Postoperative Care of Esophagectomy

Phase: N/A Priority: Normal
NCT ID: NCT03273686 Org: User:
Start: 09/15/17 End: 04/15/18 Due: 04/15/19

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT04734262 Org: User:
Start: 04/01/21 End: 06/30/24 Due: 06/30/25

Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT05860907 Org: User:
Start: 10/31/23 End: 10/31/27 Due: 10/31/28

Capecitabine in Low Risk Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06787339 Org: User:
Start: 01/15/25 End: 01/31/30 Due: 01/31/31

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06344780 Org: User:
Start: 05/20/23 End: 02/01/25 Due: 02/01/26

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Phase: N/A Priority: Normal
NCT ID: NCT06665087 Org: User:
Start: 11/30/24 End: 11/30/28 Due: 11/30/29

The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03088163 Org: User:
Start: 08/31/16 End: 08/31/18 Due: 08/31/19

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00595985 Org: User:
Start: 07/31/07 End: 01/31/09 Due: 01/31/10

To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06665334 Org: User:
Start: 10/31/24 End: 12/31/28 Due: 12/31/29

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05628038 Org: User:
Start: 11/30/22 End: 12/01/25 Due: 12/01/26

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04512534 Org: User:
Start: 11/13/20 End: 12/31/26 Due: 12/31/27

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04411524 Org: User:
Start: 07/01/20 End: 12/31/22 Due: 12/31/23

TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)

Phase: N/A Priority: Normal
NCT ID: NCT04954794 Org: User:
Start: 07/14/21 End: 04/29/24 Due: 04/29/25

Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014)

Phase: N/A Priority: Normal
NCT ID: NCT05794698 Org: User:
Start: 01/01/22 End: 08/30/24 Due: 08/30/25

Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

Phase: N/A Priority: Normal
NCT ID: NCT05306028 Org: User:
Start: 08/01/22 End: 12/31/25 Due: 12/31/26

Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC

Phase: N/A Priority: Normal
NCT ID: NCT05969171 Org: User:
Start: 08/31/23 End: 07/31/25 Due: 07/31/26

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05861271 Org: User:
Start: 06/01/23 End: 07/01/28 Due: 07/01/29

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Phase: N/A Priority: Normal
NCT ID: NCT06988592 Org: User:
Start: 05/23/25 End: 12/30/27 Due: 12/30/28

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05426850 Org: User:
Start: 06/01/21 End: 12/01/24 Due: 12/01/25

An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT00589901 Org: User:
Start: 08/31/06 End: 12/31/08 Due: 12/31/09

Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position

Phase: N/A Priority: Normal
NCT ID: NCT01144325 Org: User:
Start: 07/31/10 End: 12/31/16 Due: 12/31/17